RESUMO
This paper retrospectively reported the ethical evaluation, discussion, review and decision made by the ethics committee of Peking University Shenzhen hospital on the first case study of TCR-T technology in the treatment of advanced pancreatic cancer. The issues discussed included the nature, risk-benefit assessment, informed consent and risk control of the case. Finally, three suggestions were put forward, including strengthen the supervision of innovative treatment research projects, implement full and effective informed consent by using doctor-patient joint decision-making mode, and improve the ability of ethical substance review, in order to provide reference for the ethics committee to review clinical research projects with cutting-edge technologies such as cell therapy.